0R15 7877.0 -0.8059% 0R1E 7849.0 3.3171% 0M69 None None% 0R2V 182.7 -0.436% 0QYR 1322.0 -3.4332% 0QYP 413.62 1.2534% 0LCV 150.09 1.7559% 0RUK None None% 0RYA 1598.0 -4.7108% 0RIH 168.2 -0.6204% 0RIH 168.2 -0.6204% 0R1O 187.75 9900.0% 0R1O None None% 0QFP None None% 0M2Z 312.55 0.7089% 0VSO 26.6 -25.2914% 0R1I None None% 0QZI 471.5 -0.8412% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-10T14:42:00Z
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | -12.69400M | -23.17700M | -9.17900M | -22.57100M | -73.30400M |
| Minority interest | -1.58200M | -1.63600M | -1.31500M | 6.31M | 6.14M |
| Net income | -23.14600M | -30.45100M | -11.57600M | -22.77500M | -73.29100M |
| Selling general administrative | - | - | - | - | 0.21M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 86.75M | 83.13M | 65.58M | 54.96M | 66.00M |
| Reconciled depreciation | 37.21M | 39.06M | 24.64M | 28.54M | 83.31M |
| Ebit | -0.46500M | -4.75600M | -1.00800M | -7.67800M | -64.95000M |
| Ebitda | 36.74M | 34.30M | 23.63M | 20.86M | 18.36M |
| Depreciation and amortization | 37.21M | 39.06M | 24.64M | 28.54M | 83.31M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -5.31600M | -4.75600M | -1.00800M | -7.67800M | -64.95000M |
| Other operating expenses | 170.86M | 165.56M | 129.35M | 114.47M | 187.60M |
| Interest expense | 10.50M | 11.42M | 7.99M | 12.78M | 6.09M |
| Tax provision | 3.37M | 7.27M | 2.40M | 0.20M | -0.01300M |
| Interest income | 0.63M | 4.74M | 4.18M | 0.10M | 0.37M |
| Net interest income | -9.87400M | -15.31600M | -3.80200M | -8.27500M | -5.72800M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 3.37M | 7.27M | 2.40M | 0.20M | -0.01300M |
| Total revenue | 169.48M | 158.28M | 125.06M | 105.56M | 127.34M |
| Total operating expenses | 88.13M | 90.41M | 69.87M | 63.87M | 126.25M |
| Cost of revenue | 82.73M | 75.15M | 59.48M | 50.60M | 61.35M |
| Total other income expense net | -7.37800M | -18.42100M | -8.17100M | -14.89300M | -8.35400M |
| Discontinued operations | - | - | - | -9.17400M | -23.95900M |
| Net income from continuing ops | -16.05900M | -30.45100M | -11.57600M | -22.77500M | -73.29100M |
| Net income applicable to common shares | - | -32.08700M | -12.89100M | -32.92300M | -83.85700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 471.30M | 526.57M | 481.99M | 489.04M | 503.38M |
| Intangible assets | 103.59M | 130.54M | 130.34M | 145.76M | 167.16M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 56.38M | 46.50M | 39.37M | 16.02M |
| Total liab | 188.68M | 203.29M | 202.39M | 193.59M | 192.91M |
| Total stockholder equity | 276.40M | 313.40M | 271.71M | 289.13M | 304.33M |
| Deferred long term liab | - | 27.24M | 25.80M | 21.97M | 18.71M |
| Other current liab | 28.37M | 11.84M | 6.20M | 4.34M | 13.74M |
| Common stock | 0.74M | 0.70M | 0.67M | 0.67M | 0.56M |
| Capital stock | 0.74M | 0.70M | 0.67M | 0.67M | 0.56M |
| Retained earnings | 183.49M | -185.13600M | -154.23100M | -142.17000M | -110.91600M |
| Other liab | - | 36.99M | 29.14M | 34.40M | 40.75M |
| Good will | 102.49M | 114.72M | 98.70M | 101.25M | 108.58M |
| Other assets | - | 48.12M | 47.05M | 38.59M | 31.18M |
| Cash | 36.52M | 36.40M | 39.46M | 71.61M | 16.05M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 75.08M | 73.26M | 63.52M | 55.38M | 52.21M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 65.47M | 73.74M | 80.93M | 37.55M | 87.14M |
| Short term debt | 20.05M | 17.09M | 10.65M | 5.34M | 3.23M |
| Short long term debt | 8.48M | 5.57M | 1.61M | 2.86M | 3.10M |
| Short long term debt total | 102.00M | 110.14M | 120.39M | 109.16M | 103.19M |
| Other stockholder equity | 92.18M | 497.83M | 425.28M | 430.63M | 414.69M |
| Property plant equipment | - | 108.93M | 104.31M | 75.95M | 88.90M |
| Total current assets | 150.03M | 148.37M | 124.03M | 145.75M | 122.79M |
| Long term investments | - | - | - | - | 3.48M |
| Net tangible assets | - | 95.37M | 68.48M | 64.09M | 47.29M |
| Short term investments | - | - | - | - | - |
| Net receivables | 24.85M | 40.50M | 34.36M | 28.43M | 52.08M |
| Long term debt | 73.66M | 78.28M | 94.79M | 95.86M | 99.50M |
| Inventory | 52.85M | 55.59M | 38.07M | 34.77M | 38.63M |
| Accounts payable | 26.66M | 44.32M | 46.67M | 45.69M | 35.23M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | -28.26500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.67M | 0.56M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 21.98M | 24.01M | 24.61M | 20.33M | 15.95M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 321.27M | 378.20M | 357.96M | 343.29M | 380.59M |
| Capital lease obligations | 19.86M | 26.29M | 23.99M | 10.44M | 0.59M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -5.27200M | 1.17M | -0.56900M | 6.41M | -1.07800M |
| Change to liabilities | - | 6.95M | 5.55M | 5.01M | 3.97M |
| Total cashflows from investing activities | - | -11.21600M | -23.09000M | 30.38M | -15.32100M |
| Net borrowings | - | -17.46800M | -7.70800M | -3.87400M | 21.35M |
| Total cash from financing activities | -12.32700M | -6.92200M | -14.66900M | 30.13M | 15.98M |
| Change to operating activities | - | 1.06M | -5.42700M | -0.26000M | 0.26M |
| Net income | -21.56400M | -30.45100M | -11.57600M | -31.94900M | -83.08000M |
| Change in cash | 0.13M | -3.06100M | -32.14500M | 55.55M | -8.03900M |
| Begin period cash flow | 36.40M | 39.46M | 71.61M | 16.05M | 24.09M |
| End period cash flow | 36.52M | 36.40M | 39.46M | 71.61M | 16.05M |
| Total cash from operating activities | 20.00M | 10.81M | 5.79M | -4.05600M | -9.21100M |
| Issuance of capital stock | 13.02M | 20.74M | 0.75M | 42.98M | 0.00200M |
| Depreciation | 37.21M | 39.06M | 24.64M | 28.54M | 83.31M |
| Other cashflows from investing activities | - | 0.12M | 0.09M | 1.49M | 0.45M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 1.22M | -11.50500M | -8.98100M | -3.73300M | -10.86600M |
| Change to account receivables | - | -8.51100M | -8.17800M | 4.20M | -12.51600M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -6.87700M | 47.22M | -12.31300M | -2.70400M | 87.21M |
| Change to netincome | - | 16.82M | 5.98M | 0.40M | 21.08M |
| Capital expenditures | 6.78M | 12.72M | 22.72M | 11.41M | 15.81M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -1.05700M | -12.01200M | -11.61200M | 5.21M | -19.15300M |
| Stock based compensation | 1.00M | 1.18M | 0.83M | 1.67M | 1.18M |
| Other non cash items | 7.73M | 13.03M | 6.54M | 9.78M | 7.47M |
| Free cash flow | 13.22M | -1.91100M | -16.93100M | -15.47000M | -25.02500M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BMK Benchmark Holdings Plc |
-0.3 0.69% | 43.20 | - | - | 1.55 | 0.94 | 1.91 | 9.26 |
| HLN Haleon PLC |
-0.2 0.06% | 327.80 | 24.73 | 16.86 | 2.63 | 1.81 | 3.17 | 16.57 |
| HIK Hikma Pharmaceuticals PLC |
13.00 0.66% | 1994.00 | 33.45 | 11.14 | 1.45 | 2.32 | 1.76 | 8.98 |
| HCM HUTCHMED China Ltd |
14.00 4.14% | 352.00 | - | - | 3.22 | 3.97 | 2.39 | -19.4252 |
| INDV Indivior PLC |
5.00 0.35% | 1432.00 | - | - | 1.60 | 48.69 | 1.17 | -4.7616 |
Benchmark Holdings plc, together with its subsidiaries, engages in the provision of technical services, products, and specialist knowledge that supports the development of food and farming industries. It operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers sea bass and bream, salmon, and shrimp breeding technologies and production facilities to the harnesses industry to provide various genetic merit ova. The Advanced Nutrition segment manufactures and provides nutrition and health products to the aquaculture industry. The Health segment provides health products, including Ectosan Vet and CleanTreat medicinal sea lice solutions to the aquaculture market. The company operates in the United Kingdom, Norway, Vietnam, Iceland, the Faroe Islands, China, Ecuador, India, Canada, Greece, Chile, Turkey, rest of the Europe, and internationally. Benchmark Holdings plc was incorporated in 2000 and is headquartered in Sheffield, the United Kingdom.
4 Park Square, Sheffield, United Kingdom, S35 2PH
| Name | Title | Year Born |
|---|---|---|
| Mr. Trond Williksen | CEO & Director | 1963 |
| Ms. Septima Maguire | CFO & Director | NA |
| Ms. Ruth Layton | Co-Founder & Head of Benchmark Sustainability Science | NA |
| Mr. Neil Robertson | Head of Operations | NA |
| Ms. Ivonne Maria Gloria Cantu | Director of Investor Relations & Corp. Devel. and Head of Sustainability Working Group | 1969 |
| Ms. Jennifer Haddouk | Company Sec. & Group Legal Counsel | NA |
| Ms. Corina Holmes | Group Head of People | NA |
| Mr. Roland James Bonney | Group Lead of Key Account Management | 1964 |
| Mr. David Babington | Managing Director of Improve International | NA |
| Mr. John Marshall | Head of Health | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...